Adverse events during the Scleroderma Lung Study.
The Scleroderma Lung Study (SLS) was a 1-year, randomized, controlled trial of oral cyclophosphamide for scleroderma-related pulmonary alveolitis. It concluded that oral cyclophosphamide slowed the decline in the forced vital capacity (% predicted) and had a beneficial effect on dyspnea, skin changes, and several quality of life measures of systemic sclerosis. We now report an in-depth assessment of the toxicity of cyclophosphamide during the year of therapy and the year after therapy was completed, during which time the investigators were still masked to the treatment assignment.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Version: za2963e q8za9 q8zbb q8zc9 q8zd3 q8ze3 q8zf3 q8zg7